Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing

Loading news article.

Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing | WAPE

Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing

Article summary

Related companies

Comments —